Prosecution Insights
Last updated: October 04, 2026
Application No. 18/359,526

DNA-STABILISED METAL CLUSTER BASED NUCLEIC ACID-SENSOR WITH DISTINCT EMISSION COLOUR AND INTENSITY CHANGE UPON TARGET RECOGNITION

Final Rejection §102
Filed
Jul 26, 2023
Priority
Jul 27, 2022 — EU 22187343.3
Examiner
CHEN, STACY BROWN
Art Unit
1672
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERSITEIT LEIDEN
OA Round
2 (Final)
66%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 66% — above average
66%
Career Allowance Rate
621 granted / 940 resolved
+6.1% vs TC avg
Strong +41% interview lift
Without
With
+40.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
59 currently pending
Career history
986
Total Applications
across all art units

Statute-Specific Performance

§101
5.8%
-34.2% vs TC avg
§103
30.3%
-9.7% vs TC avg
§102
14.2%
-25.8% vs TC avg
§112
32.3%
-7.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 940 resolved cases

Office Action

§102
DETAILED ACTION Applicant’s amendment and remarks filed July 23, 2026 are acknowledged. Any prior objection or rejection that is not repeated or addressed below is either moot or withdrawn in view of Applicant’s amendment. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3-5 and 12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yang et al. (WO 2015/007293 A1, cited in the IDS filed 7/26/2023, “Yang”). The claims are summarized above and correlated with the teachings of the prior art in bold font below. Yang discloses stem-loop silver nanocluster probes that detect miRNA in biological samples (see abstract). The probe comprises a polycytosine loop sequence consisting of from 6-12 cytosine nucleotides that function as a scaffold for silver nanoclustering, a target complementary sequence comprising at least 21 nucleotides in length, and an anchoring sequence consisting of from 2-12 nucleotides, wherein part of the anchoring sequence is complementary to the target complementary sequence (see page 2, lines 5-19) (claims 1, 3 and 4). An example of Yang’s probe is in Figure 1, reproduced below: PNG media_image1.png 164 828 media_image1.png Greyscale Yang’s probe comprises a template nucleotide sequence for AgQC formation (“loop for AgNC”), a target-recognition nucleotide sequence (“sensor for miRNA-21”), and nucleotide sequence for intra-molecular hybridization (“forms loop in the absence of miRNA”) which has a stem-loop structure in the absence of a target nucleotide sequence and whose structure is disturbed when the target nucleotide sequence binds the sensor for miRNA-21 (claim 1, aspect of stem-loop structure). Figure 3 shows a full stem-loop structure and two partial stem-loop structures in the absence of a target nucleotide sequence. Silver clusters are disclosed (see page 10, lines 9-11) (claim 5). Target nucleotide concentration detected is, for example, 0.1 µM (100 nM) (see page 5, lines 9-13) (claim 12). Claim 1 now recites limitations about what will happen when the sensor is used. (Hybridization of the target nucleotide sequence with the at least one target-recognition nucleotide sequence triggers a shift in fluorescence intensity between two characteristic fluorescence maxima in fluorescence spectrum of the sensor caused by either opening of the stem-loop structure, or change in AgQC environment while maintaining the stem-loop structure of the sensor.) These limitations characterize the sensor in terms of what it will do when hybridization occurs. However, the claims are products, not methods of detecting a shift in fluorescence intensity between two characteristic fluorescence maxima (as in method claim 14). Therefore, since the prior art’s sensors meet the structural limitations of the instant claims, the claims remain rejected. In Applicant’s remarks filed July 23, 2026, Applicant argues that Yang does not teach the new limitations in claim 1 as outlined in the paragraph above. Applicant does not note any structural difference between Yang’s sensor and the instantly claimed sensor, only an intended method of use and its implications down the line. Applicant’s arguments, as they pertain to the product claims, are not persuasive. Conclusion Claims 6-11 and 13-16 are objected to for being dependent on a rejected claim but would otherwise be allowable if rewritten in independent form. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Thomas Visone, can be reached on 571-270-0684. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /STACY B CHEN/Primary Examiner, Art Unit 1672
Read full office action

Prosecution Timeline

Jul 26, 2023
Application Filed
Apr 17, 2026
Non-Final Rejection mailed — §102
Jul 23, 2026
Response Filed
Sep 25, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12699093
BIOSENSOR AND METHOD FOR DETERMINATION OF VIRUSES IN CORONAVIRUS FAMILY
3y 1m to grant Granted Aug 04, 2026
Patent 12653883
ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS
5y 1m to grant Granted Jun 16, 2026
Patent 12642846
ZIKA/DENGUE VACCINE AND APPLICATION THEREOF
4y 0m to grant Granted Jun 02, 2026
Patent 12636360
MUMPS AND MEASLES VIRUS IMMUNOGENS AND THEIR USE
3y 11m to grant Granted May 26, 2026
Patent 12622958
Virus-like particles containing RSV antigen protein and vaccines using the same
3y 6m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
66%
Grant Probability
99%
With Interview (+40.6%)
3y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 940 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month